Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aGalCer-OVA
- Development stage
- Preclinical
- Lead developer
- University of Texas Health Science Center at San Antonio
- Modality
- Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intranasal, Intravenous
01
Overview
**aGalCer-OVA** is an experimental polymeric nanoparticle cancer-vaccine formulation that co-delivers the glycolipid invariant natural killer T-cell adjuvant alpha-galactosylceramide and the model tumor antigen ovalbumin. In murine B16F10-OVA melanoma models, it activated invariant natural killer T cells, promoted tumor infiltration by invariant natural killer T cells, natural killer cells, and ovalbumin-specific CD8-positive T cells, and enhanced cytotoxic-effector production including granzyme B and perforin. It showed prophylactic and therapeutic antitumor activity in mice and was more effective when combined with anti-CTLA-4 plus anti-PD-1 checkpoint blockade. This is an academic, preclinical model immunotherapy rather than a marketed or clinical-stage product. ([academic.oup.com](https://academic.oup.com/jimmunol/article-abstract/208/Supplement_1/122.13/7940220))
- Other names
- aGalCer-OVA nanoPaGalCer-OVA nanoparticle
02
Targets
iNKT TCR (Invariant natural killer T-cell receptor)H-2Kb/SIINFEKL (Major Histocompatibility Complex class I presenting Ovalbumin 257-264)Major histocompatibility complex class II presenting ovalbumin 323-339 peptide (MHC II-OVA323-339)CD1D (Tumor-associated macrophage/myeloid-derived suppressor cell CD1d complex)
Beyond the preview
Go deeper on aGalCer-OVA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aGalCer-OVA.